156 related articles for article (PubMed ID: 30724632)
1. E2F1 as a molecular drug target in ovarian cancer.
Farra R; Dapas B; Grassi M; Benedetti F; Grassi G
Expert Opin Ther Targets; 2019 Mar; 23(3):161-164. PubMed ID: 30724632
[No Abstract] [Full Text] [Related]
2. E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets.
Huang Y; Chen R; Zhou J
Curr Cancer Drug Targets; 2016; 16(9):765-772. PubMed ID: 26881929
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
[TBL] [Abstract][Full Text] [Related]
4. RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.
Feldstein O; Ben-Hamo R; Bashari D; Efroni S; Ginsberg D
Mol Cancer Res; 2012 Sep; 10(9):1169-77. PubMed ID: 22798430
[TBL] [Abstract][Full Text] [Related]
5. E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C.
Sang XB; Zong ZH; Wang LL; Wu DD; Chen S; Liu BL; Zhao Y
Oncotarget; 2017 Feb; 8(9):14777-14793. PubMed ID: 28146423
[TBL] [Abstract][Full Text] [Related]
6. Making the most of every option in the treatment of ovarian cancer.
du Bois A
Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):1. PubMed ID: 27797623
[No Abstract] [Full Text] [Related]
7. The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy.
Ben Shachar B; Feldstein O; Hacohen D; Ginsberg D
Mol Cancer Res; 2010 Mar; 8(3):363-72. PubMed ID: 20197383
[TBL] [Abstract][Full Text] [Related]
8. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.
Moioli M; Barra F; Maramai M; Valenzano Menada M; Vellone VG; Costantini S; Ferrero S
Expert Opin Investig Drugs; 2019 Dec; 28(12):1025-1029. PubMed ID: 31726889
[No Abstract] [Full Text] [Related]
9. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.
Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W
Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861
[TBL] [Abstract][Full Text] [Related]
10. New drugs in ovarian cancer.
Fleming GF
Clin Adv Hematol Oncol; 2015 Apr; 13(4):223-5. PubMed ID: 26352580
[No Abstract] [Full Text] [Related]
11. Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells.
Hayatigolkhatmi K; Padroni G; Su W; Fang L; Gómez-Castañeda E; Hsieh YC; Jackson L; Holyoake TL; Pellicano F; Burley GA; Jørgensen HG
Blood Cells Mol Dis; 2018 Mar; 69():119-122. PubMed ID: 29217295
[No Abstract] [Full Text] [Related]
12. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells.
Laine A; Westermarck J
Clin Cancer Res; 2014 Jul; 20(14):3644-50. PubMed ID: 24788101
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in gynecologic cancers: Ready for prime time?
Seoud M; Lundqvist EÅ; Fujiwara K
Int J Gynaecol Obstet; 2015 Oct; 131 Suppl 2():S150-2. PubMed ID: 26433672
[No Abstract] [Full Text] [Related]
14. Sphingosine 1-phosphate: a potential molecular target for ovarian cancer therapy?
Dai L; Xia P; Di W
Cancer Invest; 2014 Mar; 32(3):71-80. PubMed ID: 24499107
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer: how can resistance to chemotherapy be tackled?
Karakashev S; Aird KM
Future Oncol; 2017 Dec; 13(30):2737-2739. PubMed ID: 29182383
[No Abstract] [Full Text] [Related]
16. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
17. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
19. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
Jacot W; Theillet C; Guiu S; Lamy PJ
Future Oncol; 2015; 11(4):557-9. PubMed ID: 25686112
[No Abstract] [Full Text] [Related]
20. [Impact of molecular classification on clinical management of ovarian cancer].
Hasegawa K
Gan To Kagaku Ryoho; 2015 Feb; 42(2):166-8. PubMed ID: 25834913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
